The 70–85% figure: what it measures and why it matters

Across independently published clinical cohorts, 70–85% of patients who receive a ChondroFiller injection achieve meaningful symptom relief — a figure that has held consistently across knee, hip, and small-joint studies followed for three to five years.

That range deserves a precise definition. In the research that generated it, 'meaningful' does not mean any detectable change on a scan or a marginal shift in a pain score. It means a patient-reported outcome improvement that exceeds the minimum clinically important difference (MCID) — the smallest gain that patients can reliably notice in daily life. For the commonly used IKDC knee scale, that threshold is 16.7 points; studies reporting ChondroFiller outcomes consistently show average gains of roughly 30 points, approximately double the MCID. Hip cohorts use the Harris Hip Score, where the pattern is similar. The result is a functional change patients actually feel, not a statistical artefact.

The 70–85% figure is an aggregate drawn from multiple independent cohorts, not a manufacturer-supplied success rate. It is not derived from a single trial or a single joint. The consistency across joint types and across separate research groups lends it credibility, though the evidence base — largely small-to-moderate, single-centre cohorts — means it should be read as a well-supported approximation rather than a definitive fixed number.

Functional outcomes: what patients report at three and five years

The Jerosch et al. post-market clinical follow-up provides the sharpest single anchor in the knee dataset: a mean IKDC improvement of 32.4 points at three years, with patients reaching a mean functional score of 80. Four independent cohorts report average gains of approximately 30 points on that same scale — a figure that, as established above, is roughly double the threshold at which patients reliably notice a change in day-to-day activity. To put a score of 80 on the IKDC in practical terms: patients at that level typically report walking without restriction, managing stairs comfortably, and returning to light recreational activity. That is a materially different quality of life from the baseline scores in these cohorts, where pain on routine movement is the presenting complaint.

Hip outcomes carry equivalent weight. In the Mazek 2021 prospective cohort (n=26; 21 evaluable), 81% of patients maintained good or excellent results not just at a single endpoint but continuously across the three-, four-, and five-year time points — the only dataset in the published literature to track ChondroFiller hip outcomes uninterrupted over that span. Harris Hip Score improvements of approximately 33 points have been reported in hip cohorts, a gain of similar magnitude to the IKDC improvements seen in knee studies and well above the Harris Hip Score's own clinical significance threshold.

Cross-joint coverage is a notable feature of the published evidence base. Data span knee, hip, ankle, and small joints, and broadly comparable response rates appear across those applications — consistent with the scaffold's design as a collagen matrix that supports focal cartilage repair wherever structural loss has occurred, rather than a joint-specific intervention. The breadth of the dataset strengthens confidence that the outcomes described here reflect the product's behaviour across the joint spectrum, not a finding specific to one well-studied location.

What MRI shows: structural repair inside the joint

Symptom scores tell one part of the story; MRI tells another. MOCART — the Magnetic Resonance Observation of Cartilage Repair Tissue scale — is a validated scoring system that measures how completely a defect has been filled and how well the new tissue integrates with surrounding cartilage. A score of 100 represents perfect structural repair; anything above 70 is considered good to excellent fill and integration. Published ChondroFiller cohorts consistently record MOCART scores between 70 and 87, placing most treated joints in that good-to-excellent range at follow-up.

A longitudinal dataset illustrates what is happening inside the joint over time: MOCART scores begin at 65.3 at four weeks — already reaching the boundary of the acceptable range — and rise to 81.6 at twelve months. That rising trajectory confirms the scaffold is biologically active over time, not a static implant. Structurally, the joint is still maturing well beyond the point at which functional gains plateau — by six months, most patients report stable symptom levels, yet tissue remodelling continues for one to two years as the collagen scaffold is progressively resorbed and replaced by the patient's own repair tissue.

The quality of that repair tissue is clinically significant. ChondroFiller's mechanism — acellular matrix-induced chondrogenesis, in which the scaffold recruits progenitor cells from the surrounding joint environment — promotes endogenous repair described as hyaline-like rather than fibrocartilage. Fibrocartilage, the tissue typically produced by microfracture, is mechanically inferior to native cartilage and generally considered less durable. Hyaline-like tissue is structurally closer to the original surface. The MRI evidence, taken alongside the functional data, reflects measurable biological change rather than symptom relief attributable to cushioning or placebo effect alone.

How recovery unfolds: the six-month and one-year picture

Most patients want a concrete answer: when will the improvement actually arrive?

A 2024 cohort study (n=17), tracking both Lysholm and IKDC scores, found statistically significant functional gains at three months, six months, and twelve months post-procedure. The notable finding is what did not change: there was no statistically significant difference between the six- and twelve-month readings. Functional recovery largely consolidates within the first six months.

That plateau in scores does not mean the joint has stopped changing. Structural repair tissue continues maturing on MRI beyond the six-month mark — the MOCART trajectory documented in published cohorts (65.3 at four weeks, rising to 81.6 at twelve months) reflects biological remodelling that runs on a separate, longer clock. How a patient feels and what is occurring structurally inside the joint are two different timelines, and they do not move in step.

The practical implication is a realistic and relatively compact recovery window. A six-month consolidation of functional gains compares favourably with surgical cartilage repair procedures such as autologous chondrocyte implantation (ACI), where rehabilitation typically extends to twelve to eighteen months before patients reach comparable functional milestones. Patients should expect meaningful improvement within the first three months, with the bulk of their benefit in place by six — while the biological repair process continues quietly beyond that point.

Who is most likely to respond well — and who may not

Patient selection is, by some margin, the strongest predictor of outcome in the published ChondroFiller literature — stronger than defect location, joint, or follow-up duration.

The profile that consistently produces good-to-excellent results is a focal, contained cartilage defect — typically Grade III or IV on the standard clinical grading scale — with a healthy border of surrounding cartilage, in a joint that has not yet progressed to severe osteoarthritis. Defects below approximately 2 cm² in area, in patients without advanced joint disease, represent the core indication across the published cohort evidence.

What changes the picture materially is OA stage. Patients with severe osteoarthritis — Tönnis grade 2–3 in the hip, or Kellgren-Lawrence III–IV in the knee — generally see poorer results in clinical series. The reason is biological: when the surrounding cartilage and subchondral architecture are significantly compromised, the scaffold has less healthy tissue to integrate with and fewer viable progenitor cells in the local environment to recruit. Large, diffuse damage — rather than a discrete, bordered lesion — creates the same constraints. A ChondroFiller injection is not indicated for end-stage joint disease; that is a different clinical state requiring different management.

A structured assessment is required before any patient proceeds. This means imaging (typically MRI), clinical examination, and defect mapping to confirm the size, depth, and borders of the lesion and the integrity of the surrounding joint. The assessment determines whether a focal injectable scaffold is likely to engage the repair environment it depends on.

One further variable sits alongside patient anatomy: technique. The precision of image-guided delivery, and how completely the matrix achieves defect fill at placement, influences what the scaffold can do — outcome is not determined by the product in isolation.

Evidence gaps, safety, and getting assessed in London

The post-market safety data for ChondroFiller are, on balance, reassuring. Across more than 19,000 procedures performed globally, the reoperation rate sits between 3 and 8%, and serious complications are described as rare across published clinical safety records. For a cartilage repair intervention, that profile is notable.

The evidence base behind those outcomes carries caveats worth stating plainly. Published cohorts are predominantly small-to-moderate, single-centre studies. No large, multicentre randomised controlled trial exists. No head-to-head RCT comparing ChondroFiller with microfracture or autologous chondrocyte implantation has been conducted, which means comparative efficacy claims rest on indirect inference rather than direct trial data. Follow-up data beyond five years are sparse — a material gap for anyone weighing a repair option they hope will hold for a decade or more.

What the evidence does establish, across independently conducted cohorts at three to five years, is a consistent pattern: a majority of well-selected patients achieve functional gains that substantially exceed the threshold of clinical meaningfulness, with structural repair visible on MRI and a low rate of treatment failure. The limitations do not erase that finding; they define its boundaries.

ChondroFiller has been CE-marked and in clinical use across Europe for approximately 20 years. It is not FDA-approved and is unavailable in the United States.

In the UK, Liquid Cartilage™ is delivered as an ultrasound-guided outpatient injection at the London Cartilage Clinic on Harley Street. Appointments and initial assessments can be arranged at londoncartilage.com.